GlassScriptPhysician profile
Giouzel Glodener
NPI 1528046539
$4,291.37
in general payments reported to CMS, 2019-2025
47 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $446 · 2021: $575 · 2022: $801 · 2023: $735 · 2024: $577 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $455.40 | 2019-2025 | Trintellix, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $359.11 | 2019-2021 | |
| Corium, LLC | $288.97 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $278.30 | 2021-2023 | Qelbree |
| Glaxosmithkline, LLC. | $271.96 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $198.53 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Inari Medical, INC. | $189.06 | 2022 | |
| Novo Nordisk INC | $174.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $156.30 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $148.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $147.68 | 2019-2023 | |
| Abbott Laboratories | $135.15 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $122.04 | 2019-2023 | |
| Csl Behring | $116.64 | 2019-2023 | Haegarda |
| Abbvie INC. | $104.86 | 2020-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giouzel Glodener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.